Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

CompletedOBSERVATIONAL
Enrollment

1,674

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

sunitinib malate

"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY